Patients with primary brain tumors and COVID-19: A report from the Dutch Oncology COVID-19 Consortium

Affiliations

¹ Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, the Netherlands.
² Brain Tumor Center, Department of Neurology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, the Netherlands.
³ Department of Neurology and Neurosurgery, UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht, the Netherlands.
⁴ Department of Neurology, Catharina Hospital, Eindhoven, the Netherlands.
⁵ Department of Neurology, Leiden University Medical Center, Leiden, the Netherlands.
⁶ Department of Neurology, Haaglanden Medical Center, The Hague, the Netherlands.
⁷ Department of Oncology, Isala Oncology Center, Isala, Zwolle, the Netherlands.
⁸ Department of Neurology, Amsterdam UMC, Vrije Universiteit Amsterdam, Brain Tumor Center Amsterdam, Amsterdam, the Netherlands.
⁹ Department of Oncology, Elisabeth-TweeSteden Hospital, Tilburg, the Netherlands.
¹⁰ Department of Pulmonary Medicine, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, the Netherlands.
¹¹ Department of Pulmonary Diseases GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center+, Maastricht, the Netherlands.
¹² Department of Radiology and Nuclear Medicine, Erasmus MC, Rotterdam, the Netherlands.

Karlijn de Joode et al. Neuro Oncol. 2022.

. 2022 Feb 1;24(2):326-328.

doi: 10.1093/neuonc/noab258.

¹ Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, the Netherlands.
² Brain Tumor Center, Department of Neurology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, the Netherlands.
³ Department of Neurology and Neurosurgery, UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht, the Netherlands.
⁴ Department of Neurology, Catharina Hospital, Eindhoven, the Netherlands.
⁵ Department of Neurology, Leiden University Medical Center, Leiden, the Netherlands.
⁶ Department of Neurology, Haaglanden Medical Center, The Hague, the Netherlands.
⁷ Department of Oncology, Isala Oncology Center, Isala, Zwolle, the Netherlands.
⁸ Department of Neurology, Amsterdam UMC, Vrije Universiteit Amsterdam, Brain Tumor Center Amsterdam, Amsterdam, the Netherlands.
⁹ Department of Oncology, Elisabeth-TweeSteden Hospital, Tilburg, the Netherlands.
¹⁰ Department of Pulmonary Medicine, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, the Netherlands.
¹¹ Department of Pulmonary Diseases GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center+, Maastricht, the Netherlands.
¹² Department of Radiology and Nuclear Medicine, Erasmus MC, Rotterdam, the Netherlands.

No abstract available

References

1. de Joode K, Dumoulin DW, Tol J, et al. ; DOCC Investigators. Dutch Oncology COVID-19 consortium: outcome of COVID-19 in patients with cancer in a nationwide cohort study. Eur J Cancer. 2020;141:171–184. - PMC - PubMed
1. Lee AJX, Purshouse K. COVID-19 and cancer registries: learning from the first peak of the SARS-CoV-2 pandemic. Br J Cancer. 2021;124(11):1777–1784. - PMC - PubMed
1. Saini KS, Tagliamento M, Lambertini M, et al. . Mortality in patients with cancer and coronavirus disease 2019: a systematic review and pooled analysis of 52 studies. Eur J Cancer. 2020;139:43–50. - PMC - PubMed
1. van der Veldt AAM, Oosting SF, Dingemans AC, et al. . COVID-19 vaccination: the VOICE for patients with cancer. Nat Med. 2021;27(4):568–569. - PubMed
1. Polack FP, Thomas SJ, Kitchin N, et al. ; C4591001 Clinical Trial Group. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603–2615. - PMC - PubMed